Clinical trial · Interventional
Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma
NCT00177554CI-TRIAL-00001491completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the complete response rate when CHOP-R chemotherapy in followed by Zevalin in previous untreated patients with follicular lymphoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy and Radioimmunotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Complete response rate
- timeFrame
- May 2007,May 2008, May2009, May 2010
Secondary outcomes (4)
- measure
- PET-CT conversion rate
- timeFrame
- May2007
- measure
- Frequency and severity of adverse events
- timeFrame
- May 2007
- measure
- Duration of complete response
- timeFrame
- May 2007,May 2008, May 2009, May 2010
- measure
- Time to next lymphoma therapy
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Conformed diagnosis of follicular lymphoma, grades 1,2 or 3 * No prior chemotherapy * No prior monoclonal antibody therapy * Bulky or symptomatic disease, stage II-IV * Performance status 0-2 Exclusion Criteria: * Impaired bone marrow reserve * Presence of CNS lymphoma * Serious nonmalignant disease or active infection
References
Publications (1)
- DERIVEDJacobs SA, Swerdlow SH, Kant J, Foon KA, Jankowitz R, Land SR, DeMonaco N, Joyce J, Osborn JL, Evans TL, Schaefer PM, Luong TM. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res. 2008 Nov 1;14(21):7088-94. doi: 10.1158/1078-0432.CCR-08-0529. PMID 18981007